Gabelli reiterated their buy rating on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a research note published on Wednesday morning.

TEVA has been the topic of a number of other research reports. TheStreet cut Teva Pharmaceutical Industries Limited from a c- rating to a d+ rating in a report on Friday, August 25th. ValuEngine cut Teva Pharmaceutical Industries Limited from a buy rating to a hold rating in a report on Friday, September 1st. Vetr cut Teva Pharmaceutical Industries Limited from a strong-buy rating to a buy rating and set a $31.94 target price on the stock. in a report on Monday, May 22nd. Deutsche Bank AG reiterated a buy rating and issued a $28.00 target price (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 9th. Finally, Credit Suisse Group cut Teva Pharmaceutical Industries Limited from a neutral rating to an underperform rating and reduced their target price for the company from $25.00 to $13.00 in a report on Wednesday, August 23rd. Five research analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of Hold and an average price target of $31.42.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 18.10 on Wednesday. The stock’s market cap is $18.39 billion. The company has a 50 day moving average price of $19.00 and a 200 day moving average price of $28.55. Teva Pharmaceutical Industries Limited has a 12-month low of $15.22 and a 12-month high of $51.61.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same quarter last year, the business earned $1.25 EPS. Teva Pharmaceutical Industries Limited’s revenue for the quarter was up 12.9% compared to the same quarter last year. Analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited’s (TEVA) Buy Rating Reiterated at Gabelli” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/17/teva-pharmaceutical-industries-limiteds-teva-buy-rating-reiterated-at-gabelli.html.

The company also recently declared a quarterly dividend, which was paid on Thursday, September 14th. Investors of record on Tuesday, August 29th were paid a $0.085 dividend. The ex-dividend date of this dividend was Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a yield of 1.88%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is -15.36%.

A number of large investors have recently bought and sold shares of the stock. Sii Investments Inc. WI grew its stake in Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Sii Investments Inc. WI now owns 6,739 shares of the company’s stock worth $214,000 after purchasing an additional 25 shares in the last quarter. Salem Investment Counselors Inc. grew its stake in Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. Salem Investment Counselors Inc. now owns 8,332 shares of the company’s stock worth $267,000 after purchasing an additional 32 shares in the last quarter. Security National Bank of Sioux City Iowa IA grew its stake in Teva Pharmaceutical Industries Limited by 0.4% in the second quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock worth $724,000 after purchasing an additional 87 shares in the last quarter. Bronfman E.L. Rothschild L.P. grew its stake in Teva Pharmaceutical Industries Limited by 2.6% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after purchasing an additional 94 shares in the last quarter. Finally, Sterling Investment Advisors Ltd. grew its stake in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 56.87% of the company’s stock.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.